Randomized trial · people
Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1
Checked against the paper Randomized trialPublished by PepVault
The takeaway
This large 80-week trial adds placebo-controlled evidence that retatrutide lowered weight and also eased knee osteoarthritis pain and sleep apnea events in adults with obesity.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 2339
- Published
- 2026
- Journal
- N Engl J Med
What they tested
The team tested whether weekly retatrutide lowers body weight in adults with obesity, and whether it eases knee osteoarthritis pain and sleep apnea in those who had them.
How the study was done
A phase 3, randomized, double-blind, placebo-controlled trial in 2339 adults with obesity but no diabetes, who got a weekly shot of retatrutide (4 mg, 9 mg or 12 mg) or placebo, a dummy shot, for 80 weeks. Subgroups included 574 people with knee osteoarthritis and 243 with obstructive sleep apnea.

Model. Individual results vary.
What they found
Mean body weight changed by -17.6% in the 4 mg arm, -23.7% in the 9 mg arm and -25.0% in the 12 mg arm, compared with -3.9% on placebo (P<0.001 for the 9 mg and 12 mg arms). In people with knee osteoarthritis, the WOMAC pain score (a 1 to 10 scale where higher means worse pain) fell by -3.2, -3.5 and -3.6 across the three arms versus -1.9 on placebo in the main analysis. In people with sleep apnea, the apnea-hypopnea index (breathing pauses or shallow-breathing events per hour) fell by -22.9, -34.3 and -31.7 events per hour versus -9.9 on placebo. Stomach and gut side effects were the most common.
What it doesn’t show
The trial included only adults without diabetes, and the knee and sleep apnea results come from smaller subgroups. It was funded by Eli Lilly.
The paper
Jastreboff et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026.
The compound
More studies on Retatrutide
- Retatrutide: top odds of 15% or more weight loss across 19 trialsMeta-analysis · people · 2025
- Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trialsRandomized trial · people · 2026
- Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetesRandomized trial · people · 2025
- Retatrutide: up to 82.4% less liver fat at 24 weeks in MASLD trialRandomized trial · people · 2024
- Retatrutide: 24.2% weight loss at 48 weeks in the 12 mg armRandomized trial · people · 2023
- Retatrutide: up to 8.96 kg placebo-adjusted weight loss in 12 weeksRandomized trial · people · 2022
- Every study on Retatrutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.